InSyBio taking steps to help tackle the opioid crisis through precision medicine

Posted on August 20, 2019


In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science and the OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) to utilize advanced machine learning methods to not only predict patient response to treatment but also to stratify chronic pain patients into individuals who will benefit from topical analgesics treatment and those who will not in order to personalize treatment for optimal therapeutic results. InSyBio showed that its analysis application can predict, with high accuracy (AUC 73.8-87.2%), patient response, allowing for a first-of-its-kind precision medicine approach to treating chronic pain.

Peter Hurwitz, President of Clarity Science states: "The OPERA Study showed that there are alternative pain management treatment options available for healthcare professionals to help address a patient’s pain. These options may lead to a reduced focus on Opioid prescribing and other oral analgesics that have side effects and have a significant impact on patient care and outcomes. Collaborating with InSyBio allowed us to identify, using predictive analytics, patients who are most likely to benefit from these alternative forms of treatment without having them trial the medication first, leading to faster patient response, reduced risk of treatment failure, improved patient outcomes, and a better Quality of Life. Incorporating this methodology across other health conditions will have an immense impact on global patient health and will change current strategies and approaches to healthcare treatment."

personalized_pain_therapy

As the opioid use epidemic reaches an all-time high, an option for a less addictive substitute to existing pain treatments has never been more needed. Often Opioids are over-utilized due to their established ability in treating chronic pain and a lack of a proper therapeutic alternative with comparable efficacy. However, Topical agents have the potential to provide analgesic effects without the risk of abuse, misuse, and addiction or many of the systemic adverse events associated with oral analgesics. Through the use of these topical agents, in combination with InSyBio’s superior machine learning tools, a very real option to addictive oral pain medication is enabled.

Labros Digonis, CEO of InSyBio states: "Understanding which patients could benefit from an alternative prescription not only lowers their risk of addiction but also has much larger implications on a national level through the lowering of opioid abuse and related negative consequences. The answer to this epidemic lies in an improved understanding of best treatment options and InSyBio is tackling this incredible feat by acknowledging individual variability, predicting response and stratifying patients into ideal therapeutic groups. This precision pain therapy ability is a breakthrough for the industry!"

This research has been recently presented by InSyBio CSO, Dr. Mavroudi, at the 10th International conference on Information, Intelligence, Systems and Applications (IISA 2019 – http://iisa2019.upatras.gr/).


insybio    clarity_science

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

About Clarity Science LLC: Clarity Science is an international scientific outcomes research Company assisting biopharmaceutical, specialty pharmacies, and other healthcare Companies with the coordination and execution of scientific, IRB-approved, outcomes studies. Managed by a seasoned staff of healthcare professionals, scientific researchers, outcomes statisticians, and guided by physician experts across multiple therapeutic areas, Clarity Science currently coordinates and administers outcomes studies in pain, allergy, podiatry, scar/wound healing, cardio-metabolic, psychiatry, urology, and genomic testing fields. Whether through improving treatment methodologies or identifying new ones, we aspire to make a global positive impact on patient health and to improve the quality of life for patients and their families. Our goal is to conduct scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide (www.claritysciences.com).

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .


For more News visit our InSyBio Blog.